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ABSTRACT
Background and aims: Previous clinical trials suggest
that adding non-selective beta-blockers improves the
efficacy of endoscopic band ligation (EBL) in the
prevention of recurrent bleeding, but no study has
evaluated whether EBL improves the efficacy of beta-
blockers + isosorbide-5-mononitrate. The present study
was aimed at evaluating this issue in a multicentre
randomised controlled trial (RCT) and to correlate changes
in hepatic venous pressure gradient (HVPG) during
treatment with clinical outcomes
Methods: 158 patients with cirrhosis, admitted because
of variceal bleeding, were randomised to receive
nadolol+isosorbide-5-mononitrate alone (Drug: n = 78) or
combined with EBL (Drug+EBL; n = 80). HVPG measure-
ments were performed at randomisation and after 4–6
weeks on medical therapy.
Results: Median follow-up was 15 months. One-year
probability of recurrent bleeding was similar in both
groups (33% vs 26%: p = 0.3). There were no significant
differences in survival or need of rescue shunts. Overall
adverse events or those requiring hospital admission were
significantly more frequent in the Drug+EBL group.
Recurrent bleeding was significantly more frequent in
HVPG non-responders than in responders (HVPG reduction
>20% or (12 mm Hg). Among non-responders
recurrent bleeding was similar in patients treated with
Drugs or Drugs+EBL.
Conclusions: Adding EBL to pharmacological treatment
did not reduce recurrent bleeding, the need for rescue
therapy, or mortality, and was associated with more
adverse events. Furthermore, associating EBL to drug
therapy did not reduce the high rebleeding risk of HVPG
non-responders.
ISRCTN26221020
Patients surviving a first episode of variceal
bleeding have a risk of over 60% of experiencing
recurrent haemorrhage within 2 years from the
index episode.1 As a consequence, all patients
surviving a variceal bleed must receive active
treatments to prevent rebleeding.1 A meta-analysis
of the four reported studies comparing non-
selective beta-blockers (BB) plus isosorbide-5-
mononitrate (IsMn) versus endoscopic variceal
band ligation (EBL)2–5 showed no significant
differences between these treatments in both
preventing rebleeding and in mortality. Based on
this evidence, the 2005 Baveno IV consensus
conference recommended either pharmacological
therapy with a BB¡IsMn or EBL as first-line
treatments to prevent rebleeding in patients with
cirrhosis.6 On the other hand, two randomised
trials have shown that continued nadolol admin-
istration improved the efficacy of EBL in prevent-
ing rebleeding,7 8 but did not decrease mortality.
Based in these two studies, recent guidelines have
recommended BB plus EBL as the best option for
the secondary prevention of variceal haemor-
rhage.9 10 However, these trials were underpowered
and one study was prematurely stopped after an
interim analysis despite the absence of a predeter-
mined stopping rule.8 In addition, preliminary data
from a third study failed to confirm the benefit of
combining EBL + drugs,11 and so far no study has
evaluated whether the addition of EBL improves
the efficacy of BB+IsMn.
A reduction in the hepatic venous pressure
gradient (HVPG) of at least 20% of baseline values
or to values of 12 mm Hg or below is associated
with a very low risk of rebleeding during follow-
up.12–14 In patients achieving these targets (around
40% of those receiving BB+IsMn2 15–17), adding EBL
is unlikely to enhance the beneficial effect of BB,
but certainly will increase the rate of adverse
events, so the overall benefit remains conjectural.
Therefore, the present study was aimed at
investigating, in a multicentre randomised con-
trolled trial (RCT), whether the association of EBL
to pharmacological therapy with nadolol+IsMn is
more effective than nadolol+IsMn alone in pre-
venting recurrent upper gastrointestinal bleeding
in patients with cirrhosis surviving an episode of
variceal bleeding and to establish the correlation
between changes in HVPG caused by therapy and
the clinical outcome of patients receiving or not
EBL on top of drug therapy.
METHODS
Selection of patients
This prospective RCT was conducted in six
hospitals in Spain: Hospital Clinic (Barcelona:
coordinating centre); Hospital Sant Pau
(Barcelona); Hospital Ramo´n y Cajal (Madrid);
Hospital Gregorio Maran˜o´n (Madrid); Hospital
Germans Trias y Pujol (Badalona); and Hospital
Torrecardenas (Almeria).
Patients with cirrhosis admitted between
February 2003 and October 2005 in any of the six
participating hospitals with an endoscopy-proven
oesophageal variceal bleeding were considered
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eligible for the study if they met the following criteria:
(1) successful treatment of the index bleed with vasoactive
drugs (terlipressin or somatostatin), antibiotics and endoscopic
treatment; (2) age between 18 and 75 years; (3) no previous
randomisation in the study; and (4) provided signed, informed,
written consent to participate in the study.
Exclusion criteria were: (1) failure to fulfill entry criteria;
(2) pregnancy; (3) known hepatocellular carcinoma; (4) chronic
renal failure; (5) Child–Pugh score >13 or a concomitant disease
with reduced life expectancy; (6) contraindications to BB or
IsMn; (7) previous treatment to prevent rebleeding with a
portosystemic shunt or with combined pharmacological therapy
with BB+IsMn;(8) treatment with EBL in the 3 months before
the index bled; (9) bleeding from isolated gastric or ectopic
varices; and (10) portal vein thrombosis.
Randomisation
Randomisation was performed between day 5 and day 7 of the
index bleed, after at least 48 h of haemodynamic stability
without signs of bleeding. Randomisation was stratified by
Child class (A vs BC). The randomisation sequence was
generated by computer in blocks of 8 and the code was kept
at the coordinating centre in sealed, consecutively numbered,
opaque envelopes. Randomisation was done by contacting the
coordinating centre by fax.
Baseline evaluation and general management
All patients received an endoscopic treatment to control the
acute bleeding episode. Before randomisation a full clinical
history, physical examination, electrocardiogram, chest radio-
graph, laboratory tests, ultrasonography (to discard the presence
of hepatocelular carcinoma or portal vein thrombosis) and
hepatic vein catheterisation (with measurements of hepatic
venous pressure gradient (HVPG)) were obtained according to
recommended standardised procedures.18 Immediately after
randomisation nadolol (Nad) was initiated. The dose was
increased stepwise, every 2–3 days, up to the maximum
tolerated dose or up to 240 mg/day, and then IsMn was
initiated by administering 10 mg at night-time and increased
step-wise up to a maximum of 20 mg twice a day or the
maximal tolerated dose. In general, the dose was increased if
clinically tolerated, and if systolic blood pressure was >95 mm
Hg and resting rate .50 bpm. Patients not tolerating a dose
increment were kept at the previous dose. Two weeks after
being on stable doses of Nad+IsMn the HVPG was measured
again.
In the group randomised to receive additional treatment with
EBL, the first elective session was carried out within 7 days of
randomisation. Then EBL sessions were scheduled every 10–14
days until variceal eradication (disappearance of varices or being
too small to be sucked in the banding device). EBL sessions were
performed using multiband devices; application of the bands
was started at the gastro-oesophageal junction and progressed
upwards in a helical way for approximately 5–8 cm. All
procedures were performed under conscious sedation with
midazolam (2–4 mg, intravenously) and continuous monitoring
of oxygen saturation, arterial pressure and pulse rate. Patients
received proton-pump inhibitors until reaching variceal eradica-
tion. After eradication, an endoscopic control was performed at
1, 6 and 12 month intervals and then annually. If varices
reappeared, further EBL sessions were initiated. Both groups of
patients were visited at month 1, month 3 and then every
3 months until the end of follow-up. Each visit included
anamnesis, physical examination and blood tests including
haematology and biochemistry. Ultrasonography was per-
formed at visit 1, at month 6 and every 6 months thereafter.
Patients were followed until death, liver transplantation, up to a
maximum of 2 years or up to the end of the study (1 February
2006).
End points
The main endpoint of the study was recurrent bleeding from
any source. Secondary endpoints were variceal rebleeding,
mortality (overall and mortality related to bleeding), develop-
ment of ascites, hepatorenal syndrome, hepatic encephalopathy,
development of severe side-effects, blood transfusion require-
ments, days in hospital, use of rescue treatment to prevent
rebleeding and relationship between HVPG response and
rebleeding at follow-up.
All patients were instructed to come to hospital whenever
they experienced melena or haematemesis. If bleeding was
confirmed, an emergency endoscopy was performed. The
diagnosis of variceal bleeding was done when varices were
actively bleeding or had stigmata of recent bleeding and/or if
fresh blood was observed in the stomach and varices were the
only potential source of bleeding. Bleeding was considered to be
EBL-related when endoscopy disclosed bleeding from an ulcer
secondary to previous ligation. The rebleeding episode was
treated primarily by means of vasoactive drugs (somatostatin or
terlipressin) and endoscopic treatment, preferably with EBL.
Patients with one clinically significant rebleeding (transfusion
requirements of >2 units of blood) or two less severe
rebleedings were considered treatment failures and alternative
treatments to prevent rebleeding were administered according
to their physician preference.
Table 1 Clinical characteristics of the patients at inclusion
Characteristic Drug (n = 78) Drug+EBL (n = 80)
Age (years) 56 (11)* 57 (12)*
Sex (M/F) 53/25 65/15
Aetiology (alcohol/HCV/both/
others) (no)
42/18/10/8 39/25/9/7
Active alcoholism (%) 55 50
Child A/B/C patients (no) 18/42/18 16/46/18
Child score 8.1 (1.8)* 8.2 (1.8)*
Ascites (%) 40 29
Total bilirubin (mg/dl) 2.9 (3.0)* 3.5 (7.1)*
Serum albumin (mg/dl) 29.1 (7)* 28.9 (5)*
Prothrombin ratio (%) 64 (14)* 66 (13)*
Creatinine (mg/dl) 0.8 (0.3)* 0.8 (0.3)*
Heart rate (bpm) 85 (15)* 85 (15)*
Mean arterial pressure (mm Hg) 83 (11)* 85 (12)*
HVPG (mm Hg) 20.5 (5)* 21.5 (6)*
Large varices (%) 94 91
Previous variceal bleeding (%) 13 19
Active bleeding at endoscopy{ (%) 37 33
Shock at index bled (%) 32 19
Haematocrit at index bled (%) 27 (7)* 29 (6)*
Blood units transfused at index
bled
2.9 (2.2)* 2.6 (2.7)*
Endoscopic treatment at index
bled
EBL/EIS (%) 60/40 57/43
Nadolol dose (mg/day) 102 (52)* 90 (48)*
IsMn dose (mg/day) 36 (9)* 36 (10)*
*Results given as the mean (SD). {Before applying endoscopic therapy.
EBL, endoscopic band ligation; EIS, endoscopic injection sclerotherapy; HVPG, hepatic
venous pressure gradient.
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Sample size calculation
The actuarial risk of recurrent bleeding at 1 year with BB+IsMn
is approximately 32%.2–5 The study hypothesised that by adding
EBL the risk for recurrent bleeding could be decreased to 15%.
Because adding EBL to drug therapy would have only a rational
in the case that this approach would be better than the use of
drugs alone, the sample size was calculated using a one-sided
test.19 20 Seventy-six patients per group were calculated to detect
the differences above mentioned with alpha = 0.05 and beta
= 0.20.
Statistical analysis
The SPSS statistical package was used for this analysis. Data are
reported as means with standard deviations. Categorical
variables were compared using the Fisher’s exact test.
Actuarial probability curves were constructed by using the
Kaplan–Meier method and compared with the log-rank test.
Stepwise Cox regression analysis was used to identify indepen-
dent predictors for recurrent bleeding and survival. Relative
hazards and the 95% confidence interval (CI) are given.
Statistical significance was established at a p value ,0.05. The
intent-to-treat strategy was used in the analysis of the results.
RESULTS
Three hundred and forty-two patients were initially considered
for the study. A total of 182 patients were excluded for the
reasons shown in fig 1. Therefore, finally, 160 patients were
randomised. Two patients were excluded early after randomisa-
tion, one patient because of prehepatic portal hypertension and
one because of a diffuse hepatocelullar carcinoma with portal
vein thrombosis; so, finally, there were 158 evaluable patients:
78 in the Nad+IsMn (Drug) group and 80 in the Nad+IsMn+EBL
(Drug+EBL) group.
There were no relevant differences at entry in clinical or
endoscopic characteristics (table 1).
In addition, HVPG, severity of the index bled and doses of
Nad and IsMn administered were also similar in both groups
(table 1). The use of EBL or sclerotherapy as a treatment to
control acute bleeding was based in physician preferences. There
were no significant differences in the severity of the bleeding
episode between patients receiving EBL or sclerotherapy, as
suggested by similar haematocrit at admission: 27.3 (SD 7) vs 29
(SD 6)%; shock: 29.5% vs 24.6%; blood transfusion: 2.8 (SD 2)
vs 2.5 (SD 2) units (all NS). However, the finding of active
bleeding at the time of the procedure may have influenced the
choice, since active bleeding was more frequent in patients
receiving sclerotherapy than in those treated with EBL (58% vs
28%).
Four patients, two in each group were lost to follow-up after
a mean follow-up of 4 months (range: 0.3–10 months) without
developing any end-point. The remaining patients were
followed until recurrent bleeding, death, liver transplantation,
2 years of follow-up or up to the end of the study. Mean follow-
up was 14.4 (SD 7.8) months in the Drug group and 15.3 (SD
8.3) months in the Drug+EBL group (NS). Three and two
patients received OLT in the Drug and in the Drug+EBL group,
respectively. According to attendance to scheduled visits,
scheduled EBL sessions and heart rate monitoring, 87% of
patients in the Drug group and 80% of the Drug+EBL group
(NS) were compliant to the allocated treatment.
Variceal eradication was achieved in 60 of the 80 patients of
the Drug+EBL group after a mean of 2 (SD 1) EBL sessions and
after a median of 21 days (range: 7–189). The number of
additional EBL sessions to achieve eradication was not
significantly different in patients receiving EBL or sclerotherapy
as the acute endoscopic treatment for the index bled (1.8 (SD
1.4) vs 2.2 (SD 1.1) EBL sessions; p = 0.3). In 20 of the 60
patients achieving eradication (33%), varices reappeared after a
median of 191 days (range: 54–740 days) after eradication.
Variceal eradication was not achieved in 20 patients (because
recurrent bleeding (n = 9), death (n = 3), lost to follow-up
(n = 2), consent withdrawal (n = 2) or despite multiple EBL
sessions (n = 4). Overall, in the Drug+EBL group 192 EBL
sessions were performed and 977 bands used.
Rebleeding
Twenty-seven patients in the Drug group and 22 patients in the
Drug+EBL group rebled during follow-up (NS). There were no
significant differences in the 1 year (33% vs 26%; absolute risk
difference (ARD): 27%; 95% CI: 223% to +9%) and 2 year
(46% vs 31%; ARD: 215%: 95% CI: 236% to +6%); p = 0.3)
actuarial probability of recurrent bleeding from any source (fig 2)
In five patients recurrent bleeding was secondary to oesophageal
ulcers related to endoscopic treatment (four in the Drug+EBL
group and one in the Drug group) in four to portal hypertensive
gastropathy (three in the Drug+EBL group and one in the Drug
group) and in one, from the Drug+EBL group, no endoscopy was
Figure 1 Enrolment of patients included in the study. BB, beta-
blockers; EBL, endoscopic band ligation; HCC, hepatocelullar carcinoma;
IsMn, isosorbide-5-mononitrate; Nad, nadolol; TIPS, transjugular
intrahepatic portosystemic shunt. Figure 2 Actuarial probability of remaining free of recurrent bleeding
from any source. EBL, endoscopic band ligation.
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performed. (table 2)) As a consequence, when considering only
patients with confirmed variceal bleeding, rebleeding was
significantly higher in the Drug group than in the Drug+EBL
group (table 2).
Twenty-two patients in the Drug group and 17 patients in
the Drug+EBL group (NS) had treatment failure. Eight and nine
patient, respectively, required derivative treatments as a rescue
therapy. Other treatments received to prevent further rebleed-
ing are depicted in table 2.
Severity of rebleeding was similar in patients treated with
Drug or Drug+EBL, as shown by transfusion requirements,
rescue treatments required or mortality related to bleeding
(table 2). On univariate analysis, Child–Pugh class, prothrombin
time, bilirubin, previous variceal bleeding, transfusion require-
ments and use of sclerotherapy as endoscopic treatment of the
index bleed were the variables significantly related with an
increased risk of recurrent bleeding. The multivariate analysis
using the Cox model disclosed bilirubin (HR, 1.05; 95% CI, 1.01
to 1.07), previous variceal bleeding (HR, 2.07; 95% CI, 1.1 to 4),
transfusion requirements (HR, 1.16; 95% CI, 1.05 to 1.28) and
use of sclerotherapy (HR, 2; 95% CI, 1.1 to 3.5) as independent
predictors of the risk of rebleeding from any source. However,
there were also no differences in recurrent bleeding between
both treatment groups if patients treated with sclerotherapy
were deleted from the analysis.
Other complications of cirrhosis and portal hypertension
There were no significant differences among both groups in the
1 year and 2 year actuarial probability of new or worsening
ascites (Drug: 13.8% and 20%, Drug+EBL: 21% and 26%;
p = 0.17). In addition there were no significant differences in the
incidence of hepatorenal syndrome (4.1% vs 5.3%; NS), hepatic
encephalopathy (19.2% vs 22.7%; NS) or hepatocellular
carcinoma (8.6% vs 5.4%; NS). There were also no significant
differences in days of hospitalisation for any reason during
follow-up (table 2).
Survival
There were no significant differences in the 1 year and 2 year
actuarial probability of survival (Drug: 82% and 77%;
Drug+EBL: 87 and 74%, NS; fig 3). One-year ARD, 25% (95%
CI, 218% to +8%), 2 year ARD, +3% (95% CI, 218% to +24%).
There were also no significant differences in the causes of death
(table 2).
On univariate analysis, Child–Pugh class, previous encephalo-
pathy and baseline HVPG were the variables significantly
related with increased mortality. When these variables were
entered on a multivariate analysis using the Cox’s model, only
the Child–Pugh class independently predicted mortality.
Adverse effects
Overall, the number of patients with adverse events was
significantly higher in the Drug+EBL (61%) than in the Drug
group (32%; p,0.01) (table 3). In five patients of the Drug+EBL
versus none of the Drug group the side effect was severe enough
to require hospital admission (p,0.05) (table 3). There were no
significant differences in the number of patients requiring drug
withdrawal (10 in the Drug+EBL vs six in the Drug group) or
drug dose reduction during follow-up (12 in the Drug+EBL vs 12
in the Drug group).
Clinical haemodynamic correlations
Baseline HVPG was done in all patients. One hundred and thirty-
five patients had a second HVPG a median of 33 days after the
initial HVPG. The second HVPG measurement was not done in 23
patients (13 in the Drug and 10 in the Drug+EBL group) because of
early recurrent bleeding (n = 14), death (n = 3), refusal of consent
(n = 2), early lost to follow-up (n = 1), failure to schedule the
measurement (n = 2) and in one patient it was not possible to get
an adequate wedged hepatic pressure due to hepatic vein-to-vein
communications. Overall, 17 of the 23 patients without a second
HVPG measurement rebleed during follow-up (15 from oesopha-
geal varices) and 12 died.
In the 135 patients with repeat HVPG measurements, initial
HVPG was 20.3 (SD 5) mm Hg and decreased to 17.3 (SD 4.4)
mm Hg after beta-blockade (12.7%; p,0.001). Forty-eight
patients (36%) had a decrease in HVPG to ,12 mm Hg or by
.20% from baseline (responders), while these targets were not
Table 2 Primary and secondary endpoints of the study according to
allocated therapy
Drug
(n = 78)
Drug+EBL
(n = 80) p Value
Rebleeding from any source 27 22 NS
Child A 8 3 0.11
Child B+C 19 19 NS
Rebleeding from portal
hypertension sources
Variceal rebleeding 25 14 0.03
Portal hypertensive gastropathy 1 3
Post-endoscopic therapy 1 post-EIS{ 4 post-EBL ulcer
Source unknown 1
Blood units transfused at
rebleeding
4.1 (4)* 3.6 (2.4)* NS
Rescue treatments (no)
Portosystemic shunts (TIPS/
surgery)
6/2 9/0
EBL ¡ Nad+IsMn 14 8
Days in hospital during follow-up 10 (16)* 11 (21)* NS
Mortality 15 16 NS
Recurrent bleeding 8 5 NS
Sepsis 3 2 NS
Liver failure 1 4 NS
Others 3 5 NS
*Results given as the mean (SD).
{Endoscopic injection sclerotherapy (EIS) was used for the treatment of the index
bleed.
EBL, endoscopic variceal band ligation; ISMN, isosorbide-5-mononitrate; PHG, portal
hypertensive gastropathy.
Figure 3 Actuarial probability of survival. EBL, endoscopic band
ligation.
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achieved in the remaining 87 patients (non-responders). For
purposes of clinical hemodynamic correlations,two patients
who developed complete portal vein thrombosis on follow-up
were censored when complete portal vein thrombosis was
detected.
One-year and 2 year actuarial probability of recurrent
bleeding either from any source or from varices were signifi-
cantly higher in non-responders than in responders (recurrent
bleeding: 27% and 35% vs 11% and 17%: p = 0.03; fig 4A;
variceal rebleeding: 22% and 28% vs 5% and 10%; p = 0.01).
Importantly, there were no significant differences between non-
responders treated with Drug vs Drug+EBL with regards to
1 year and 2 year actuarial probability of rebleeding from any
source (Drug: 29% and 37% vs 23% and 32% in Drug + EBL;
p = 0.9; fig 4B) or from varices (Drug: 27% and 35% vs 16% and
20% in Drug + EBL; p = 0.4). In addition, adding EBL did not
reduce rebleeding or improve survival in HVPG-responders.
DISCUSSION
Variceal bleeding is a frequent complication of portal hyperten-
sion associated with high mortality and high risk of recurrence if
no preventive treatment is initiated.21 Combined pharmacolo-
gical therapy with non-selective BB plus IsMn or EBL are both
considered equivalent and good alternatives in the secondary
prevention of variceal bleeding.6 21 Based on two studies on a
relatively low number of patients (122 and 80, respectively),7 8
showing that patients treated with nadolol + EBL had a reduced
risk of variceal rebleeding, although not of mortality, than
patients treated only with EBL, it has been suggested that the
combination of non-selective beta-blockers (with or without
nitrates) plus EBL could be the best treatment option to prevent
variceal rebleeding.9 10 21 This was also supported by a recent
meta-analysis,22 although a recent study, only available in
abstract form,11 has challenged this recommendation by show-
ing no benefit in rebleeding rate or mortality of the combination
of EBL+ propranolol over EBL alone. It should be noted,
however, that these previous studies evaluated the role of
adding drugs to EBL as compared with EBL alone, which does
not allow the conclusion that such combination therapy is
better than drug therapy alone. Because of this we aimed at
investigating whether adding EBL may improve the efficacy of
the combination of non-selective BB plus IsMn.
The results of the present study fail to show significant
differences in the rate of recurrent bleeding among patients
treated with Drug+EBL or Drugs alone. The best results were
observed in Child A patients receiving Drug+EBL, the popula-
tion with an expected lower rebleeding risk, although neither in
this subgroup the benefit from adding EBL was statistically
significant.
Recurrent bleeding was especially frequent among patients
who received injection sclerotherapy as the endoscopic treat-
ment for the index bleed. Indeed, multivariate analysis showed
the use of sclerotherapy during the index bleed to be
independent predictor of recurrent bleeding. It is possible that
a session of sclerotherapy within the previous 10 days may
favour deeper ulcers after EBL and ulcer bleeding. In addition, it
has been reported that sclerotherapy produces an increase in
portal pressure that is maintained during at least 5 days, while
EBL only produced a transient increase in portal pressure that
returns to pretreatment values within 48 h.23 This increase in
portal pressure may favour portal hypertension related rebleed-
ing. Therefore our results further support the recommenda-
tion6 9 10 24 that EBL should be the endoscopic treatment of
choice during the acute bleeding episode, and suggest that
avoiding sclerotherapy during the index bleed may reduce the
incidence of non-variceal rebleeding episodes.
When only patients with confirmed variceal rebleeding were
considered (a secondary end-point of this study), patients
treated with Drug+EBL had a lower probability of rebleeding
than patients treated with Drug alone. It is important to
remark, however, that in clinical practice, it is often difficult to
distinguish between bleeding from varices or bleeding from
ligation ulcers. Even if, theoretically, it should be possible to
correctly distinguish these two events, the clinical relevance of
this is limited: both are due to portal hypertension and may be
life-threatening for the patient. A similar situation applies to
portal hypertensive gastropathy. Moreover, the possible slight
benefit in preventing variceal rebleeding of adding EBL to drug
therapy was at the expense of having more side effects, some of
them requiring hospital admission (mainly due to rebleeding
from oesophageal ulcers), and of a huge number of endoscopic
procedures to perform the scheduled EBL sessions and to
evaluate variceal recurrence. This makes very likely a greater
cost in the group Drug+EBL than in the group treated with
Drug only.
Important enough, there were no significant differences in
survival among patients treated with Drugs+EBL or Drugs
Table 3 Side effects observed in patients treated with Nad+IsMn or
Nad+IsMn+EBL
Nad+IsMn Nad+IsMn+EBL p Value
Overall 25/78 (32%) 49/80 (61%) ,0.01
Requiring withdrawal of
Nad/IsMn
Hypotension 4 4*2
Impotence 0 1
Bronchospasm 1 0
Glaucoma 1 0
Asthenia 0 2
Hypoglycaemia 0 2{
Diarrhoea 0 1*1
Requiring reduction of
Nad/IsMn dose
Hypotension 3 5*5
Impotence 0 1*1
Asthenia 7 3
Bronchospasm 1 0
Bradycardia 1 0
Diarrhoea 0 1
Dizziness 0 2*2
No treatment modification
Oedemas 3 0
Astenia 1 2
Cephalea 2 1
Dyspnoea 1 0
Hypotension 0 1
Impotence 0 2
Dizziness 0 3*1
Related to EBL
Post-EBL ulcer bleeding 4{, *2
Severe dysphagia 5*3
Glotis oedema 1*1
Asymptomatic post-EBL ulcer 20*6
*Number of patients having more than one side effect.
{Requiring hospitalisation (Nad+IsMn+EBL: one hypoglycaemic coma and four post-
EBL ulcer bleeding).
EBL, endoscopic band ligation; IsMn, isosorbide-5-mononitrate; Nad, nadolol.
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alone. Indeed, the degree of liver failure, evaluated by the
Child–Pugh classification, was the only independent predictor
of survival.
The results of the present study confirm that HVPG
responders exhibit a significantly lower rebleeding rate.1 12
However, and contrary to what has been suggested, adding
EBL to drug therapy failed to reduce the risk of recurrent
bleeding. These findings are in agreement with previous
observations already suggesting that adding EBL may not be
the optimal approach to improve the outcome of HVPG non-
responders2 17 25 and support the view that HVPG non-respon-
ders are a special high-risk population that may benefit from a
more aggressive approach, such as an early decision for TIPS.
This, however, should be evaluated in RCTs.
In summary, the results of the present study show that
adding EBL to pharmacological treatment fails to significantly
reduce the incidence of recurrent bleeding, the need of rescue
therapy or mortality, and is associated with more adverse events
and probably higher costs that the use of pharmacological
treatment alone. Associating EBL to drug therapy did not
modify survival and did not improve the worse prognosis of
HVPG non-responders.
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